SEC Form SC 13G filed by Oxford Immunotec Global PLC
$OXFD
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Oxford Immunotec Global PLC
(Name of Issuer)
Common Stock
(Title of Class of Securities)
G6855A103*
(CUSIP Number)
January 31, 2021
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☒ Rule 13d-1(b)
☐ Rule 13d-1(c)
☐ Rule 13d-1(d)
☒ Rule 13d-1(b)
☐ Rule 13d-1(c)
☐ Rule 13d-1(d)
* CUSIP number not available. CINS provided.
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect
to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of
Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
CUSIP No. G6855A103
|
|
13G
|
|
Page 2 of 5 Pages
|
||||||||
|
|
|
|||||||||||
|
1.
|
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Grandeur Peak Global Advisors, LLC 90-0732232 |
|
|
||||||||
|
2.
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions) (a) ☐ (b) ☐ |
|
|
||||||||
|
3.
|
|
SEC USE ONLY
|
|
|
||||||||
|
4.
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Utah |
|
|
||||||||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
|
5.
|
|
SOLE VOTING POWER
570,836 |
||||||||
|
|
6.
|
|
SHARED VOTING POWER
-0- |
|||||||||
|
|
7.
|
|
SOLE DISPOSITIVE POWER
570,836 |
|||||||||
|
|
8.
|
|
SHARED DISPOSITIVE POWER
-0- |
|||||||||
|
9.
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
570,836 |
|
|
||||||||
|
10.
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ☐ |
|
|
||||||||
|
11.
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
2.23% |
|
|
||||||||
|
12.
|
|
TYPE OF REPORTING PERSON (see instructions)
IA |
|
|
||||||||
|
|
||||||||||||
|
CUSIP No. G6855A103
|
|
13G
|
|
Page 3 of 5 Pages
|
|
|
|
|
Item 1.
|
|
(a)
|
Name of Issuer
Oxford Immunotec Global |
|
|
||
|
|
(b)
|
Address of Issuer’s Principal Executive Offices
700 Nickerson Road, Suite 200
Marlborough, MA 01752
|
|
|
Item 2.
|
|
(a)
|
Name of Person Filing
Grandeur Peak Global Advisors, LLC
|
|
|
||
|
|
(b)
|
Address of the Principal Office or, if none, residence
136 South Main Street, Suite 720 Salt Lake City, UT 84101
|
|
|
||
|
|
(c)
|
Citizenship
Not Applicable |
|
|
||
|
|
(d)
|
Title of Class of Securities
Common Stock |
|
|
||
|
|
(e)
|
CUSIP Number
G6855A103 |
|
|
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether
the person filing is a:
(e) [X] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
Item 4. Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the
issuer identified in Item 1.
|
|
(a)
|
|
Amount beneficially owned: 570,836
|
|
|
|
||||
|
|
(b)
|
|
Percent of class: 2.23%
|
|
|
|
||||
|
|
(c)
|
|
Number of shares as to which the person has:
|
|
|
|
||||
|
|
|
|
(i)
|
Sole power to vote or to direct the vote 570,836
|
|
|
||||
|
|
|
|
(ii)
|
Shared power to vote or to direct the vote -0-
|
|
|
||||
|
|
|
|
(iii)
|
Sole power to dispose or to direct the disposition of 570,836
|
|
|
||||
|
|
|
|
(iv)
|
Shared power to dispose or to direct the disposition of -0-
|
|
|
||||
Item 5. Ownership of Five Percent or Less of a Class.
As of January 31, 2021 the beneficial interest decreased more than 5% since the previous filing. Issuer was acquired
on March 9, 2021.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not Applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being
Reported on By the Parent Holding Company.
Not Applicable.
Item 8. Identification and Classification of Members of the Group.
Not Applicable.
Item 9. Notice of Dissolution of Group.
Not Applicable.
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired
and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
|
CUSIP No. G6855A103
|
|
13G
|
|
Page 5 of 5 Pages
|
|
|
|
|
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information
set forth in this statement is true, complete and correct.
| 5/7/2021 | |
| Date | |
| /s/ Amy Hone | |
| Signature | |
| Amy Hone / Deputy CCO | |
| Name/Title | |